Abstract
The incidence, severity and tolerability of dry mouth was compared in 790 women with overactive bladder who were treated with extended-release oxybutynin chloride 10 mg/day or extended-release tolterodine tartrate 4 mg/day for 12 weeks in a multicenter, double-blind, parallel-group study. Dry mouth was the most common adverse event associated with treatment, with an incidence rate of 28.1% in the oxybutynin group and 21.6% in the tolterodine group (P = 0.039). The majority of dry mouth events were mild in both treatment groups. Severe dry mouth occurred in 1.5% and 0.5% of patients in the oxybutynin and tolterodine groups, respectively (P = 0.173). Seven patients on extended-release oxybutynin and 4 patients on extended-release tolterodine discontinued treatment due to dry mouth (P = 0.380). The results of this analysis showed that dry mouth was common with both treatments, but most events were mild; there was no difference in the rate of severe dry mouth or in the rate of withdrawal due to dry mouth.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
YE Yarker KL Goa A. Fitton (1995) ArticleTitleOxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor stability Drugs Aging 6 243–262 Occurrence Handle7620236
R. Appell (1997) ArticleTitleClinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis Urology 50 IssueIDSuppl 90–96 Occurrence Handle10.1016/S0090-4295(97)00599-2 Occurrence Handle9426760
E Versi R Appell D Mobley et al. (2000) ArticleTitleDry mouth with conventional and controlled-release oxybutynin in urinary incontinence Obstet Gynecol 95 718–721 Occurrence Handle10.1016/S0029-7844(99)00661-4 Occurrence Handle10775736
L Rentzhog SL Stanton L Cardozo et al. (1998) ArticleTitleEfficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study Br J Urol 81 42–48 Occurrence Handle9467475
TO Närhi JH Meurman A. Ainamo (1999) ArticleTitleXerostomia and hyposalivation: causes, consequences and treatment in the elderly Drugs Aging 15 103–116 Occurrence Handle10495070
FC Astor KL Hanft JO. Ciocon (1999) ArticleTitleXerostomia: a prevalent condition in the elderly Ear Nose Throat J 78 476–479 Occurrence Handle10429321
WJ Loesche J Bromberg MS Terpenning et al. (1995) ArticleTitleXerostomia, xerogenic medications and food avoidances in selected geriatric groups J Am Geriatr Soc 43 401–407 Occurrence Handle7706631
NL Rhodus J. Brown (1990) ArticleTitleThe association of xerostomia and inadequate intake in older adults J Am Diet Assoc 90 1688–1692 Occurrence Handle2131338
G Sathyan MB Chancellor SK. Gupta (2001) ArticleTitleEffect of OROS ® controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride Br J Clin Pharmacol 52 409–417 Occurrence Handle10.1046/j.0306-5251.2001.01463.x Occurrence Handle11678784
RU Anderson D Mobley B Blank et al. (1999) ArticleTitleOnce daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence J Urol 161 1809–1812 Occurrence Handle10.1097/00005392-199906000-00020 Occurrence Handle10332441
MB Chancellor RA Appell G Sathyan SK. Gupta (2001) ArticleTitleA comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate Clin Ther 23 753–760 Occurrence Handle10.1016/S0149-2918(01)80024-2 Occurrence Handle11394733
P Abrams R Freeman C Anderstrom A. Mattiasson (1998) ArticleTitleTolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder Br J Urol 81 801–810 Occurrence Handle9666761
HP Drutz RA Appell D Gleason et al. (1999) ArticleTitleClinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder Int Urogynecol J 10 283–289 Occurrence Handle10.1007/s001929970003
RA Appell P Sand R Dmochowski et al. (2001) ArticleTitleOBJECT Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study Mayo Clin Proc 76 358–363 Occurrence Handle11322350
Detrol® tolterodine tartrate tablets prescribing information. Pharmacia & Upjohn Company, Kalamazoo, MI, July, 2002. Available at: http://www.detrolla.com/files/Detrol.pdf. Accessed September 24, 2003.
AC Diokno RA Appell PK Sand et al. (2003) ArticleTitleProspective, randomized, double-blind, study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial Mayo Clin Proc 78 687–695 Occurrence Handle12934777
K Waldeck B Larsson KE. Andersson (1997) ArticleTitleComparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland J Urol 157 1093–1097 Occurrence Handle10.1097/00005392-199703000-00113 Occurrence Handle9072550
J Douchamps F Derenne A Stockis et al. (1988) ArticleTitleThe pharmacokinetics of oxybutynin in man Eur J Clin Pharmacol 35 515–520 Occurrence Handle10.1007/BF00558247 Occurrence Handle3234461
SK Gupta G. Sathyan (1999) ArticleTitlePharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin J Clin Pharm 39 22–29
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Armstrong, R.B., Luber, K.M. & Peters, K.M. Comparison of Dry Mouth in Women Treated with Extended-Release Formulations of Oxybutynin or Tolterodine for Overactive Bladder. Int Urol Nephrol 37, 247–252 (2005). https://doi.org/10.1007/s11255-004-4703-7
Issue Date:
DOI: https://doi.org/10.1007/s11255-004-4703-7